Pub Date : 2024-12-01Epub Date: 2024-08-22DOI: 10.1097/JU.0000000000004200
Ting Yu, Yu Yang, Dan Shan, Jun Li, Dong Chen
{"title":"Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.","authors":"Ting Yu, Yu Yang, Dan Shan, Jun Li, Dong Chen","doi":"10.1097/JU.0000000000004200","DOIUrl":"10.1097/JU.0000000000004200","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"914-916"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-09-06DOI: 10.1097/JU.0000000000004227
Mustafa Soytas, Rafael Sanchez-Salas
{"title":"Editorial Comment.","authors":"Mustafa Soytas, Rafael Sanchez-Salas","doi":"10.1097/JU.0000000000004227","DOIUrl":"10.1097/JU.0000000000004227","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"871-872"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-20DOI: 10.1097/JU.0000000000004323
Sean P Elliott
{"title":"Trauma and Genital and Urethral Reconstruction.","authors":"Sean P Elliott","doi":"10.1097/JU.0000000000004323","DOIUrl":"https://doi.org/10.1097/JU.0000000000004323","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004323"},"PeriodicalIF":5.9,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-20DOI: 10.1097/JU.0000000000004324
Sean P Elliott
{"title":"Trauma and Genital and Urethral Reconstruction.","authors":"Sean P Elliott","doi":"10.1097/JU.0000000000004324","DOIUrl":"https://doi.org/10.1097/JU.0000000000004324","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004324"},"PeriodicalIF":5.9,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-20DOI: 10.1097/JU.0000000000004320
Sam S Chang
{"title":"Urologic Oncology: Bladder, Penis, and Urethral Cancer and Basic Principles of Oncology.","authors":"Sam S Chang","doi":"10.1097/JU.0000000000004320","DOIUrl":"https://doi.org/10.1097/JU.0000000000004320","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004320"},"PeriodicalIF":5.9,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-19DOI: 10.1097/JU.0000000000004335
Pedro Ramos, João P Brás, Carolina Dias, Mafalda Bessa-Gonçalves, Francisco Botelho, João Silva, Carlos Silva, Luís Pacheco-Figueiredo
Purpose: Alternative, non-invasive, cost-effective methods to complement or serve as substitutes to current standard of care (SOC) procedures in non-muscle invasive bladder cancer (NMIBC) follow-up, are needed. Uromonitor® is a urine biomarker test detecting bladder cancer (BC) recurrence through the screening of TERT, FGFR3 and KRAS hotspot mutations. The aim of the current study is to assess Uromonitor® performance comparing it to the current SOC methods.
Materials and methods: 528 NMIBC surveillances from 439 patients were enrolled in the study. All subjects underwent SOC methods and provided a urine sample for Uromonitor® analysis before undergoing cystoscopy. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for recurrence and compared to the gold-standard cystoscopy plus trans-urethral resection (TURBT) histopathology.
Results: Uromonitor® displayed a sensitivity of 87% (74-95, 95% CI), with only 6 out of 47 recurrences failing to be detected, a specificity of 99% (98-100) PPV of 93% (82-98) and a NPV of 99% (97-99). Cystoscopy showed a total of 22 (32%) false positives not confirmed by TURBT, while Uromonitor® presented only three positive tests where no lesions were found. Overall recurrence rate was 8.9% (n=47) among 528 total screenings. Sensitivity, specificity, PPV and NPV values for Uromonitor® remained high across all NMIBC grades and stages.
Conclusions: Uromonitor® represents a reliable tool in the detection of NMIBC recurrence in patients undergoing routine surveillance, regardless of stage and grade. To our knowledge, this is the largest single-center study assessing Uromonitor®´s performance, thus validating its usefulness in clinical practice.
{"title":"Uromonitor®: Clinical Validation and Performance Assessment of a Urinary Biomarker within the Surveillance of Non-Muscle Invasive Bladder Cancer Patients.","authors":"Pedro Ramos, João P Brás, Carolina Dias, Mafalda Bessa-Gonçalves, Francisco Botelho, João Silva, Carlos Silva, Luís Pacheco-Figueiredo","doi":"10.1097/JU.0000000000004335","DOIUrl":"https://doi.org/10.1097/JU.0000000000004335","url":null,"abstract":"<p><strong>Purpose: </strong>Alternative, non-invasive, cost-effective methods to complement or serve as substitutes to current standard of care (SOC) procedures in non-muscle invasive bladder cancer (NMIBC) follow-up, are needed. Uromonitor® is a urine biomarker test detecting bladder cancer (BC) recurrence through the screening of <i>TERT</i>, <i>FGFR3</i> and <i>KRAS</i> hotspot mutations. The aim of the current study is to assess Uromonitor® performance comparing it to the current SOC methods.</p><p><strong>Materials and methods: </strong>528 NMIBC surveillances from 439 patients were enrolled in the study. All subjects underwent SOC methods and provided a urine sample for Uromonitor® analysis before undergoing cystoscopy. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for recurrence and compared to the gold-standard cystoscopy plus trans-urethral resection (TURBT) histopathology.</p><p><strong>Results: </strong>Uromonitor® displayed a sensitivity of 87% (74-95, 95% CI), with only 6 out of 47 recurrences failing to be detected, a specificity of 99% (98-100) PPV of 93% (82-98) and a NPV of 99% (97-99). Cystoscopy showed a total of 22 (32%) false positives not confirmed by TURBT, while Uromonitor® presented only three positive tests where no lesions were found. Overall recurrence rate was 8.9% (n=47) among 528 total screenings. Sensitivity, specificity, PPV and NPV values for Uromonitor® remained high across all NMIBC grades and stages.</p><p><strong>Conclusions: </strong>Uromonitor® represents a reliable tool in the detection of NMIBC recurrence in patients undergoing routine surveillance, regardless of stage and grade. To our knowledge, this is the largest single-center study assessing Uromonitor®´s performance, thus validating its usefulness in clinical practice.</p>","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004335"},"PeriodicalIF":5.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-19DOI: 10.1097/JU.0000000000004317
Kathy H Huen, Carol Davis-Dao
{"title":"Reply: Health Vulnerabilities of Spina Bifida Patients: Transition From Adolescents to Adults.","authors":"Kathy H Huen, Carol Davis-Dao","doi":"10.1097/JU.0000000000004317","DOIUrl":"10.1097/JU.0000000000004317","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004317"},"PeriodicalIF":5.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号